Allergan PLC. (AGN-N)

(A Top Pick September 14/17- Down 22%.) This was a high-risk position. They sold a drug to a native band and then they leased the rights back to circumvent potential generic competition. Something cheeky and probably that is why the stock sold off. Their strength is still in Botox and aesthetics. He doesn’t see that changing or being threat. He still likes it. Management is under the gun.

Form a valuation standpoint, trading at 10 times forward earnings with high single digit growth rate. But the stock keeps falling down. He would be very careful with this. Could be a value trap.

They are the maker of Botox. They have a drug for dry eye syndrome that will come off patent but his analysis of the case for losing all revenue from the drug has them still doing well. They have a good drug pipeline. (Analysts’ target: $225.00).

Their number 1 product is Botox and their number 2 product is eye drops, and there is some competition coming from generics for their eyedrops drug. Thinks that is what has been hurting the stock recently. When the technicals are working against you where a stock has fallen below the 200-day moving average, and the price is below both the 50 day and 100 day, technically you want to step away.

(Market Call Minute.) A broken stock and he would Sell it and move on.

We are in a structural bull market for equities. We are skating through the two toughest months of the year without much volatility. Don’t buy a company that has been put into the penalty box. Stocks that have broken down have an army of people who just want to get their money back.

They are known for Botox. Aesthetics is a big part of their business as well as a great urology business and Gastro Intestinal business. They sold their urology business and reinvested their cash into R&D. It is very inexpensive. (Analysts’ target: $271.50).

This has things like Botox, etc., but also have some things on the pharmaceutical side. He felt that they had a great quarter. Made 10 acquisitions in the past year with the proceeds of the generics they sold to Teva. Trading around 13X forward earnings, so not terribly expensive. He likes this one.

He likes the pharmaceuticals. They are under a bit of pressure from legislation on repricing, but thinks most of that is priced in. He would say “yes” for this one.

(Top Pick Nov 29/16, Up 28.87%) He still likes it despite the return. They are very diligent at returning to shareholders. They have been making strategic acquisitions and their pipeline is full. He continues to like it.

(A Top Pick Aug 17/16. Down 13.44%.) A terrific company, and shows up as the highest quality company in its group. Unfortunately, they got painted by the specialty pharmaceutical brush. It is getting a bit of a reprieve right now. He still likes this. It has one of the best growth profiles of any of the specialty pharmaceutical companies. The majority of its businesses are not subject to the same type of price controls that could come under government scrutiny.

United Therapeutic (UTHR-Q) or Allergan (AGN-N)? This is a tough one because they are 2 very different companies. Of the 2, this is a much larger company and more broadly-based.